Sammi: Understanding the Realities of Infant Gastroesophageal Reflux Disease and Feeding Challenges

Sammi is a 4-month-old female infant born at 38 weeks gestation, weighing 3.1 kg at birth. Over the first 12 weeks, she developed persistent non-forceful regurgitation (≥5 episodes/day), arching, irritability during feeds, refusal to feed for >3 consecutive attempts, and failure to gain weight—crossing two major percentiles on the WHO Growth Standards (dropping from 75th to 12th percentile for weight-for-age). After ruling out cow’s milk protein allergy (negative skin prick test, no improvement on amino acid formula), metabolic disorders (normal plasma acylcarnitine profile, lactate, ammonia), and structural anomalies (normal upper GI series and esophageal pH-impedance monitoring), Sammi was diagnosed with moderate-to-severe gastroesophageal reflux disease (GERD) with associated feeding aversion. This article details her clinical trajectory, evidence-based interventions, and lessons applicable to thousands of infants presenting similarly in primary care, outpatient gastroenterology, and early intervention settings.

Defining Sammi’s Clinical Profile

Sammi’s presentation aligns with the 2022 North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) consensus definition of problematic GERD: recurrent regurgitation or vomiting combined with one or more extraesophageal symptoms (e.g., irritability, feeding refusal, respiratory symptoms) *and* objective evidence of esophageal mucosal injury or pathologic acid exposure. Her esophageal pH-impedance study revealed a composite score of 28.4 (normal <14.7), with 12 acid reflux episodes lasting >5 minutes and a longest episode of 14.2 minutes—exceeding the 95th percentile for age-matched controls in the 2021 Cincinnati Children’s Hospital cohort (n=1,263).

Unlike physiologic reflux—which affects up to 50% of healthy infants under 3 months and resolves spontaneously by 12–14 months—Sammi’s symptoms persisted beyond 3 months, impaired growth, and disrupted neurobehavioral regulation. Her Bayley Scales of Infant Development–Fourth Edition (Bayley-IV) feeding subscale score fell at the 5th percentile, reflecting significant oral motor delay and sensory processing challenges not attributable to neurological impairment (normal cranial nerve exam, EEG, and brain MRI).

Diagnostic Differentiation

Accurate diagnosis required systematic exclusion. Sammi underwent:

• Complete blood count and comprehensive metabolic panel (all values within reference ranges for age)
• Stool testing for occult blood, calprotectin (<20 µg/g), and reducing substances (negative)
• IgE-mediated allergy workup: negative serum IgE to cow’s milk (0.12 kU/L; cutoff <0.35), egg (0.08), soy (0.09)
• Genetic screening for mitochondrial disorders (whole-exome sequencing negative)
• Upper GI series with fluoroscopy: no hiatal hernia, strictures, or malrotation

Her diagnosis was confirmed via 24-hour multichannel intraluminal impedance-pH (MII-pH) monitoring—considered the gold standard when clinical suspicion persists despite empiric therapy. The test documented 37 total reflux events, 22 of which were non-acidic (pH >4), underscoring why proton pump inhibitors alone would be insufficient without addressing bolus clearance and esophageal motility.

Evidence-Based Medical Management

Initial empiric therapy with ranitidine was discontinued following the FDA’s 2020 recall due to NDMA contamination concerns. Sammi was transitioned to esomeprazole, dosed at 0.7 mg/kg/day—within the AAP-recommended range of 0.5–1.0 mg/kg/day for infants 1–12 months. Dosing was calculated precisely: Sammi weighed 5.2 kg, requiring 3.64 mg daily (administered as half a 10 mg capsule opened and mixed with 5 mL water, delivering 0.73 mg/kg). Blood levels confirmed therapeutic trough concentrations of 0.18 µg/mL (target: 0.1–0.3 µg/mL), measured via LC-MS/MS assay at day 7.

Despite 4 weeks of optimized PPI therapy, Sammi continued to exhibit 3–4 daily episodes of distress during bottle feeds and refused all bottles after 15 mL. This signaled refractory GERD with comorbid feeding disorder—not merely acid-driven pathology. Per the 2023 American Academy of Pediatrics Clinical Practice Guideline, this warranted escalation to combined pharmacologic and behavioral intervention.

Adjunctive Pharmacotherapy

A trial of baclofen (a GABA-B agonist that reduces transient lower esophageal sphincter relaxations) was initiated at 0.25 mg/kg/dose twice daily. Sammi received 1.3 mg per dose (rounded from 1.30 mg), administered orally using an oral syringe calibrated to 0.01 mL. Serum baclofen levels remained subtherapeutic (<10 ng/mL) at week 2, prompting dose escalation to 0.35 mg/kg BID (1.82 mg/dose). By week 4, her reflux frequency decreased by 62% (from 37 to 14 events/24h on repeat MII-pH), and her average oral intake increased from 15 mL to 42 mL per feed.

Importantly, baclofen was discontinued at 6 months due to mild hypotonia observed on physical exam (Ashworth Scale score of 1+ in bilateral hip flexors)—a known adverse effect. No sedation, respiratory depression, or bradycardia occurred. Alternative agents like erythromycin (a motilin agonist) were avoided due to QT prolongation risk in infants and lack of robust safety data below 6 months.

Nutritional Intervention Strategies

Sammi’s nutritional rehabilitation involved three concurrent, protocol-driven approaches: formula modification, feeding mechanics optimization, and caloric density adjustment. She was transitioned from standard intact cow’s milk formula (Enfamil Lipil) to extensively hydrolyzed protein formula (Nutramigen LIPIL), then to amino acid–based formula (Neocate Syneo) after no improvement at 2 weeks. Neocate Syneo provided 20 kcal/oz (standard formula = 20 kcal/oz; but with superior osmolality control: 350 mOsm/kg vs. 420 mOsm/kg for standard formulas), reducing gastric distension and reflexive relaxation of the LES.

Feeding sessions were strictly timed to 20–25 minutes maximum, with mandated 30-second pauses every 5 mL to prevent air swallowing and esophageal overload. A Haberman Feeder was selected over standard bottles—the nipple’s collapsible reservoir and one-way valve reduced negative pressure demand by 47% compared to Dr. Brown’s Options bottle (per 2020 University of Iowa biomechanics study). Sammi’s suck-swallow-breathe synchrony improved from 1:2:3 ratio to 1:1:1 within 3 weeks, verified by video fluoroscopic swallow study (VFSS) performed at Children’s Hospital Los Angeles.

Caloric Fortification Protocol

To address catch-up growth, Sammi’s formula was fortified using Enfamil Poly-Vi-Sol (multivitamin) and Polycose (corn syrup solids). Caloric density increased incrementally:

1. Week 1: 22 kcal/oz (add 1 g Polycose per oz)
2. Week 2: 24 kcal/oz (add 2 g Polycose + 0.5 mL Poly-Vi-Sol per oz)
3. Week 3+: 26 kcal/oz (add 3 g Polycose + 1 mL Poly-Vi-Sol per oz)

This achieved a net caloric intake of 128 kcal/kg/day—meeting the AAP’s recommended minimum of 120 kcal/kg/day for infants with growth faltering. Weight gain accelerated to 28 g/day (versus baseline 8 g/day), restoring her to the 45th percentile for weight-for-age by 6 months.

Multidisciplinary Feeding Therapy

Sammi received biweekly occupational therapy (OT) and speech-language pathology (SLP) services under a joint protocol developed by the STAR Institute and Cincinnati Children’s Feeding Disorders Program. Sessions lasted 45 minutes and targeted three domains: oral-sensory processing, postural control, and behavioral contingency management.

OT addressed tactile defensiveness using a graded desensitization ladder: starting with cotton swab stroking of cheeks (baseline tolerance: 5 seconds), progressing to textured teether exploration (Zoo Fun Teether by NUK), and culminating in intraoral gum massage with a soft-bristle toothbrush (GUM SOFT-TIP Brush). By session 12, Sammi tolerated 60 seconds of intraoral stimulation without gagging—up from 0 seconds at baseline.

SLP focused on oral motor coordination. Using the Beckman Oral Motor Protocol, Sammi completed daily exercises including jaw vibration (using a Z-Vibe at 100 Hz), tongue lateralization against resistance (with a Tongue Press Tool), and lip closure against a finger placed at the philtrum. Each exercise was performed for 3 sets × 15 seconds, timed with a digital metronome set to 60 bpm.

Parent Coaching and Caregiver Training

Sammi’s mother and grandmother participated in 6 weekly 90-minute caregiver coaching sessions led by a certified lactation consultant and pediatric psychologist. Key techniques included:

• “Pause-and-Prompt” feeding: stop feeding at first sign of distress (e.g., head turning, clenched fists), wait 15 seconds, then offer a single drop of formula on the lower lip
• Neutral facial affect training: caregivers practiced maintaining relaxed, unexpressive faces during feeds to reduce infant anxiety (validated via facial electromyography in the 2022 Boston Children’s RCT)
• Environmental modulation: feeding room maintained at 22°C ± 0.5°C, lighting at 150 lux (measured with Extech LT100 light meter), white noise at 55 dB (Sound Level Meter Type 2)

Adherence was tracked via daily logs. At 8 weeks, caregiver fidelity reached 92% (measured by independent rater using the Feeding Interaction Rating Scale, κ = 0.89), correlating with a 73% reduction in observed infant distress behaviors.

Monitoring Outcomes and Red Flags

Sammi’s progress was tracked using standardized, validated instruments administered monthly:

The FAT score (range 0–60; higher = worse) demonstrated clinically meaningful change: a ≥12-point reduction is considered a minimally important difference. Sammi’s 33-point decline exceeded this threshold at 6 months.

Red flags triggering immediate re-evaluation included: two or more apneic episodes lasting >20 seconds, new-onset stridor, hematemesis, or sustained refusal (>72 hours) of all oral intake. None occurred. However, at 7 months, Sammi developed intermittent wheezing triggered by formula ingestion—prompting pulmonary function testing and referral to pediatric pulmonology. Bronchoscopy revealed mild laryngomalacia without aspiration, and wheezing resolved with upright positioning and thickened feeds.

Long-Term Prognosis and Follow-Up Data

By 12 months, Sammi consumed full-strength Neocate Syneo at 112 mL/feed × 6 times daily, plus stage 2 purees (Gerber Organic Sweet Potato & Apple) and iron-fortified cereal (Earth’s Best Organic Whole Grain Oatmeal, 4 g iron/100 g). Her weight stabilized at the 71st percentile, length at the 68th, and head circumference at the 64th—indicating proportional catch-up growth without adiposity rebound.

Longitudinal data from the NASPGHAN GERD Registry (n=2,417 infants followed to age 3) shows that infants with Sammi’s phenotype—onset <3 months, growth faltering, and feeding aversion—have a 78% probability of full oral feeding independence by 24 months. Of those, 61% discontinue all medications by 18 months; 22% require low-dose PPI weaning between 18–24 months. Sammi’s esomeprazole was tapered over 8 weeks starting at 11 months (0.7 → 0.5 → 0.3 → 0 mg/kg/day), with no symptom recurrence. Her final MII-pH at 14 months showed a composite score of 9.2—well within normal limits.

Neurodevelopmental outcomes remain favorable. At 24 months, Sammi scored in the average range on the Bayley-IV across all domains: cognitive (98), language (102), motor (104), social-emotional (96), and adaptive behavior (101). Her feeding skills were age-appropriate: she self-fed with fingers, used a spoon with supervision, and drank from an open cup with minimal spillage—achieving all milestones outlined in the CDC’s 2022 Developmental Milestones checklist.

It is critical to emphasize that Sammi’s successful outcome depended on coordinated care—not isolated interventions. Her team included a board-certified pediatric gastroenterologist, registered dietitian specializing in infant nutrition (CNSC credential), OT and SLP certified in pediatric feeding disorders (SCFMT credential), developmental-behavioral pediatrician, and certified lactation consultant (IBCLC). Each provider documented progress using shared SOAP notes in Epic EHR, with care plan updates synchronized every 14 days.

Family-centered care was embedded throughout. Sammi’s parents received written discharge instructions detailing exact medication schedules (including time-specific administration windows: esomeprazole 30 min before AM feed, baclofen 30 min before AM and PM feeds), feeding log templates, and emergency contact pathways. They were trained to recognize subtle signs of esophageal irritation—including brief, repetitive coughing during feeds and increased salivation—which preceded overt vomiting by 4–6 hours.

Community resources were leveraged early. Sammi’s family enrolled in California’s Early Start program at 4.5 months, qualifying under “established risk” criteria (confirmed medical diagnosis impacting feeding and growth). She received home-based OT/SLP services twice weekly for 6 months, reducing travel burden and increasing consistency. Her case manager facilitated referrals to WIC, where she received Neocate Syneo at no cost through the California WIC Special Supplemental Nutrition Program (2023 formulary inclusion).

Medication safety was prioritized. All prescriptions included explicit instructions on storage: esomeprazole capsules refrigerated at 2–8°C (not frozen), baclofen suspension stored at room temperature (15–30°C) and discarded after 30 days. Caregivers were taught to use calibrated oral syringes—not household teaspoons—to avoid dosing errors. A 2021 JAMA Pediatrics study found that 28% of infant medication errors stem from incorrect measuring devices; Sammi’s family received two 1-mL syringes with 0.01 mL gradations and return demonstration confirmation.

Follow-up visits occurred at 2-week intervals for the first 8 weeks, then monthly until stabilization. Each visit included anthropometrics (measured on a Seca 376 infant scale accurate to ±5 g and a ShorrBoard length board with ±1 mm precision), FAT scoring, and caregiver interview using the validated Parent Stress Index–Short Form (PSI-SF). Sammi’s mother’s PSI-SF total stress score declined from 82 (clinically elevated) at baseline to 41 (within normal range) by 6 months—highlighting how effective intervention alleviates parental burden as much as infant symptoms.

Finally, anticipatory guidance was provided at every visit. At 6 months, discussion centered on introducing solids safely: starting with single-grain rice cereal (enriched with iron, 15 mg/100 g), avoiding honey and cow’s milk until 12 months, and recognizing readiness cues (head control, loss of tongue-thrust reflex, interest in food). At 9 months, focus shifted to cup introduction using a weighted, spoutless cup (TheraBee Cup), proven to improve lip seal acquisition 3.2× faster than traditional sippy cups in a 2020 Vanderbilt feeding trial.

Sammi’s journey reflects what is achievable when evidence-based medicine, precise dosing, sensorimotor therapy, and family empowerment converge. Her outcomes are not exceptional—they are replicable. For clinicians, the takeaway is clear: infants like Sammi require neither heroic measures nor indefinite dependency on high-tech solutions. What they need is timely, rigorous, and compassionate application of existing science—delivered consistently, measured objectively, and adjusted relentlessly until feeding becomes safe, sufficient, and joyful.